- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06384807
En fas 1/2-studie av PBI-410 i avancerade solida tumörer
En fas 1/2, först i människa, dosupptrappning och dosexpansionsstudie av PBI-410 hos deltagare med avancerade solida tumörer
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Chief Medical Officer
- Telefonnummer: 203-404-0410
- E-post: clinicaltrials@biohavenpharma.com
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- Site-113
-
La Jolla, California, Förenta staterna, 92093
- Rekrytering
- Site-112
-
Palo Alto, California, Förenta staterna, 94304
- Rekrytering
- Site-111
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20016
- Rekrytering
- Site-114
-
-
Florida
-
Miami, Florida, Förenta staterna, 33176
- Rekrytering
- Site-103
-
Orlando, Florida, Förenta staterna, 32827
- Rekrytering
- Site-105
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Site-115
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30912
- Rekrytering
- Site-110
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Site-109
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63108
- Avslutad
- Site-101
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Rekrytering
- Site-117
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73117
- Rekrytering
- Site-116
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Rekrytering
- Site-108
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Site-107
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Rekrytering
- Site-104
-
-
Utah
-
West Valley City, Utah, Förenta staterna, 84119
- Rekrytering
- Site-106
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- Site-102
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
-
Male or female participants aged ≥18 years.
-
Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.
-
Measurable disease (per RECIST 1.1).
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):
- Hemoglobin ≥9 g/dL
- Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
- Platelets >100,000/mm3
- Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
- Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
- Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
- International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
- Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
-
Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
BHV-1510 in Combination with specific inclusion criteria:
- histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
- received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.
Key Exclusion Criteria:
- Women who are pregnant or lactating.
- Clinically significant intercurrent disease.
- Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
- Has clinically significant corneal disease.
- Requires supplemental oxygen for daily activities.
- Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
- Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
- Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
- History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
- Has current or previously treated leptomeningeal carcinomatosis.
- Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.
BHV-1510 in Combination Specific Exclusion Criteria:
- Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
- Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Prior allogeneic stem cell or solid organ transplantation.
- Patients with history of myocarditis.
- Presence of cardiovascular disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: BHV-1510 Monoterapi Doseskalering
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andra namn:
BHV-1510 will be administered on Day 1 every 2 weeks
Andra namn:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andra namn:
|
|
Experimentell: BHV-1510 i kombination med Cemiplimab dosökning
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andra namn:
BHV-1510 will be administered on Day 1 every 2 weeks
Andra namn:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andra namn:
cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1: Number of patients with adverse events (AEs)
Tidsram: Through study completion, estimated as an average of 47 months
|
Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Tidsram: Approximately 15 months
|
Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Approximately 15 months
|
|
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Fas 1 och 2: Maximal plasmakoncentration (CMAX) av BHV-1510, total antikropp och nyttolast (BHC-0080269)
Tidsram: Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
|
|
Fas 1 och 2: Område under koncentrationen kontra tidskurva från slutet av infusion till den sista mätbara koncentrationen (AUCLAST) av BHV-1510, total antikropp och nyttolast
Tidsram: Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
|
|
Fas 1 och 2: Område under koncentrationen kontra tidskurva över doseringsintervallet (Auctau) av BHV-1510, total antikropp och nyttolast
Tidsram: Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
|
|
Fas 1 och 2: Elimineringshalveringstid (T1/2) av BHV-1510, total antikropp och nyttolast
Tidsram: Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
|
|
Fas 1 och 2: Trough Concentration (CTROUGH) av BHV-1510, total antikropp och nyttolast
Tidsram: Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
Upp till 8 tidpunkter, men inte överstiger, 22 dagar i cykler 1 och 3
|
|
|
Fas 2: Effekter av BHV-1510 monoterapi och nyttolast på QTC-intervallet med hjälp av Fridericia's Correction Method (QTCF) och på andra EKG-parametrar (hjärtfrekvens [HR], PR och QRS-intervall)
Tidsram: Ungefär 15 månader
|
Ungefär 15 månader
|
|
|
Fas 1 och 2: Arean under koncentrations-tidskurvan extrapolerad till oändligheten (AUCinf) för BHV-1510, totalt antikropp och last
Tidsram: Upp till 8 tidpunkter, men inte överstigande, 22 dagar i Cykel 1
|
Upp till 8 tidpunkter, men inte överstigande, 22 dagar i Cykel 1
|
|
|
Fas 1 och 2: Total kroppsclearance (CL) efter IV-administrering eller skenbar total kroppsclearance (CL/F) efter SC-administrering av BHV-1510 och totalt antikropp
Tidsram: Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
|
|
Fas 1 och 2: Procentuell biotillgänglighet (%F) efter SC-administrering av BHV-1510 och totalt antikropp
Tidsram: Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
|
|
Fas 1 och 2: Distributionsvolym vid jämviktstillstånd (Vss) efter IV-administrering eller skenbar distributionsvolym vid jämviktstillstånd (Vss/F) efter SC-administrering av BHV-1510 och totalt antikropp
Tidsram: Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
Upp till 8 tidpunkter, men inte mer än 22 dagar i cykel 1 och 3
|
|
|
Phase 1: ORR
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Duration of Response (DoR)
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1 and 2: Immunogenicity of BHV-1510
Tidsram: Through study completion, estimated as an average of 47 months
|
Incidence of ADA at baseline and post-treatment, including ADA titer |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsram: Through study completion, estimated as an average of 47 months
|
OS is defined as the time period from the start of administration to death due to any cause |
Through study completion, estimated as an average of 47 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Chief Medical Officer, Biohaven Pharmaceuticals, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BHV1510-101 (PBI-410-101)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .